Literature DB >> 10052699

High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues.

L Alvarez-Cedrón1, M L Sayalero, J M Lanao.   

Abstract

A specific and selective high-performance liquid chromatography (HPLC) technique that requires few manipulations, and is readily adaptable to analysis for a large series of samples, has been developed for the determination of the concentration of the anticancer drug doxorubicin (DXR) in rat serum and tissues. The biological samples were efficiently deproteinised and resolved from a reversed-phase nucleosil C18 column with fluorescence detection. The validation study of the proposed method was successfully carried out in an assay range of between 5 and 5000 ng/ml and was subsequently implemented in a pharmacokinetic study of DXR in Wistar rats that were treated by intravenous administration of the drug.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10052699     DOI: 10.1016/s0378-4347(98)00475-7

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  12 in total

1.  Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy.

Authors:  Robert D Arnold; Jeanine E Slack; Robert M Straubinger
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-09-05       Impact factor: 3.205

2.  Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.

Authors:  Stuart Ibsen; Yongxuan Su; John Norton; Eran Zahavy; Tomoko Hayashi; Stephen Adams; Wolf Wrasidlo; Sadik Esener
Journal:  J Mass Spectrom       Date:  2013-07       Impact factor: 1.982

3.  Effect of ketoprofen and indomethacin on methotrexate pharmacokinetics in mice plasma and tumor tissues.

Authors:  Yasmine M Elmorsi; Sahar M El-Haggar; Osama M Ibrahim; Mokhtar M Mabrouk
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-11-17       Impact factor: 2.441

4.  Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow.

Authors:  Amanda J Stolarz; Mustafa Sarimollaoglu; John C Marecki; Terry W Fletcher; Ekaterina I Galanzha; Sung W Rhee; Vladimir P Zharov; V Suzanne Klimberg; Nancy J Rusch
Journal:  J Pharmacol Exp Ther       Date:  2019-08-22       Impact factor: 4.030

5.  Distribution of doxorubicin in rats undergoing ultrasonic drug delivery.

Authors:  Bryant J Staples; William G Pitt; Beverly L Roeder; Ghaleb A Husseini; Deepthi Rajeev; G Bruce Schaalje
Journal:  J Pharm Sci       Date:  2010-07       Impact factor: 3.534

6.  Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.

Authors:  Rui Xue Zhang; Tian Zhang; King Chen; Ji Cheng; Paris Lai; Andrew M Rauth; K Sandy Pang; Xiao Yu Wu
Journal:  J Vis Exp       Date:  2017-10-05       Impact factor: 1.355

7.  Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer.

Authors:  Jia Lin; Yan Yu; Sarah Shigdar; Ding Zhi Fang; Jun Rong Du; Ming Q Wei; Andrew Danks; Ke Liu; Wei Duan
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

8.  A Simple and Sensitive HPLC Method for Fluorescence Quantitation of Doxorubicin in Micro-volume Plasma: Applications to Pharmacokinetic Studies in Rats.

Authors:  Marjan Daeihamed; Azadeh Haeri; Simin Dadashzadeh
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

9.  Improved efficacy and reduced toxicity of doxorubicin encapsulated in sulfatide-containing nanoliposome in a glioma model.

Authors:  Jia Lin; Sarah Shigdar; Ding Zhi Fang; Dognxi Xiang; Ming Q Wei; Andrew Danks; Lingxue Kong; Lianghong Li; Liang Qiao; Wei Duan
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240

10.  Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery.

Authors:  Dongxi Xiang; Sarah Shigdar; Andrew G Bean; Matthew Bruce; Wenrong Yang; Motilal Mathesh; Tao Wang; Wang Yin; Phuong Ha-Lien Tran; Hadi Al Shamaileh; Roberto A Barrero; Pei-Zhuo Zhang; Yong Li; Lingxue Kong; Ke Liu; Shu-Feng Zhou; Yingchun Hou; Aina He; Wei Duan
Journal:  Theranostics       Date:  2017-09-20       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.